Key Takeaways
- Cardinal Health (CAH) reported adjusted EPS of $2.91 for Q4 2026, significantly beating the analyst consensus of $2.42.
- The company issued fiscal year 2027 guidance for adjusted EPS of $12.40 to $12.60, well above the Wall Street estimate of $12.06.
- Quarterly revenue reached $63.7 billion, a 6% year-over-year increase, though it slightly missed the $65.16 billion expectation.
- Management announced a massive $5.0 billion increase to its share repurchase authorization, signaling strong confidence in future cash flows.
- Adjusted operating income for the quarter rose to $935 million, surpassing the $817.8 million estimate behind double-digit profit growth across all segments.
Strong Earnings Performance and Margin Expansion
Cardinal Health (CAH) delivered a robust fourth-quarter performance for fiscal year 2026, characterized by a substantial earnings beat and expanding margins. The company reported adjusted earnings per share (EPS) of $2.91, representing a 40% increase over the prior year. This figure included a $0.31 per share benefit from a one-time tariff refund; however, even when excluding this impact, the adjusted EPS of $2.60 comfortably cleared the analyst consensus of $2.42.
The Pharmaceutical and Specialty Solutions segment remained the primary engine of growth, with revenue rising 6% to $58.8 billion. Segment profit for this division surged 21% to $645 million, driven by strong performance in brand and specialty pharmaceutical products. Investors reacted positively to the results, with shares rising nearly 4% in pre-market trading as the market digested the significant bottom-line outperformance.
Fiscal 2027 Guidance and Strategic Growth
Looking ahead, Cardinal Health (CAH) provided an optimistic outlook for fiscal year 2027. The company expects adjusted EPS between $12.40 and $12.60, which implies a 13% to 15% growth rate from the adjusted 2026 base. This guidance exceeds the $12.06 analysts had projected, reflecting management's confidence in continued operational leverage and the integration of recent acquisitions.
The company's 2027 projections include contributions from the recently completed acquisition of Strive Medical and the pending purchase of AdaptHealth's diabetes health business. CEO Jason Hollar noted that all five operating segments achieved double-digit profit growth in 2026, describing the year as a "standout" for the company's disciplined strategic execution.
Capital Allocation and Shareholder Returns
Cardinal Health (CAH) continues to prioritize shareholder returns through aggressive capital allocation. During fiscal 2026, the company completed $1.4 billion in share repurchases and recently approved a new $5.0 billion authorization. This brings the total remaining repurchase capacity to approximately $6.4 billion as of August 2026.
In addition to buybacks, the Board of Directors maintained its commitment to dividends, declaring a regular quarterly dividend of $0.5158 per share. The company ended the fiscal year with a strong liquidity position, reporting $5.17 billion in operating cash flow and $4.97 billion in adjusted free cash flow, providing ample flexibility for further "tuck-in" acquisitions and internal investments in automation and robotics.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.